Comparison analyses of global burden of colorectal cancer
10.3760/cma.j.cn112152-20240308-00102
- VernacularTitle:全球结直肠癌疾病负担比较分析
- Author:
Jingjing LI
1
;
Yunmeng ZHANG
1
;
Yuting JI
1
;
Jie WU
1
;
Qianyun JIN
1
;
Zhuowei FENG
1
;
Hongyuan DUAN
1
;
Xiaomin LIU
1
;
Zhangyan LYU
1
;
Fengju SONG
1
;
Yubei HUANG
1
Author Information
1. 国家恶性肿瘤临床医学研究中心 天津市恶性肿瘤临床医学研究中心 天津市肿瘤分子流行病重点实验室 天津医科大学肿瘤医院肿瘤流行病与生物统计研究室，天津 300060
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Burden of disease;
Incidence;
Mortality;
GLOBOCAN 2022
- From:
Chinese Journal of Oncology
2025;47(4):308-315
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the incidence, mortality, survival patterns, and distribution characteristics of modifiable risk factors for colorectal cancer in selected global regions.Methods:Secondary analysis was conducted using data from the GLOBOCAN database and previous literature. We described the number of cases and age-standardized rates (ASRs) of incidence and mortality for colorectal cancer in China, the United States, the United Kingdom, and globally in 2022 and 2020, with gender-stratified analysis. ASRs were calculated using Segi's world standard population. Temporal trends in 5-year net survival rates were compared across three periods (2000-2004, 2005-2009, 2010-2014) among countries. Regional distribution differences in colorectal cancer deaths attributable to modifiable risk factors by gender were assessed in China.Results:In 2022, global colorectal cancer incidence and mortality were estimated at 1.926 million new cases and 904 000 deaths. China accounted for 27% of both global incidence (517 000 cases) and mortality (240 000 deaths). China's age-standardized incidence rate (20.1 per 100 000) was lower than those of the United States (27.0 per 100 000) and the UK (30.9 per 100 000). However, China's mortality rate (8.6 per 100 000) exceeded that of the US (7.9 per 100 000) but was lower than the UK (11.8 per 100 000). Compared to 2020, China demonstrated significant mortality reductions in 2022: males declined from 14.8 to 10.9 per 100 000, females from 9.4 to 6.5 per 100 000. Five-year net survival rates in China improved across periods for colon cancer (51.4%, 55.6%, 57.6%) and rectal cancer (49.5%, 52.5%, 56.9%), yet remained consistently lower than US and UK rates. Modifiable risk factors contributed to 45.1% of male and 41.4% of female colorectal cancer deaths in China, with marked regional disparities.Conclusions:China exhibits higher colorectal cancer incidence and mortality than global averages, with survival gaps persisting compared to developed nations. Regionally tailored comprehensive prevention strategies are essential to reduce disease burden through risk factor modification and optimized clinical management.
